miRNA profile at diagnosis predicts treatment outcome in patients with B-chronic lymphocytic leukemia: A FILO study

During many years, chemo-immunotherapy fludarabine-cyclophosphamide-rituximab (FCR) was the gold standard for first line treatment of medically fit patients with symptomatic B-chronic lymphocytic leukemia (CLL). Over the last decade, targeted biotherapies have revolutionized the treatment of B-CLL p...

Descripción completa

Detalles Bibliográficos
Autores principales: Duroux-Richard, Isabelle, Gagez, Anne-Laure, Alaterre, Elina, Letestu, Rémi, Khalifa, Olfa, Jorgensen, Christian, Leprêtre, Stéphane, Tchernonog, Emmanuelle, Moreaux, Jérôme, Cartron, Guillaume, Apparailly, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618812/
https://www.ncbi.nlm.nih.gov/pubmed/36325355
http://dx.doi.org/10.3389/fimmu.2022.983771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618812/
https://www.ncbi.nlm.nih.gov/pubmed/36325355
http://dx.doi.org/10.3389/fimmu.2022.983771

Ejemplares similares